- AU$92.05bn
- AU$107.79bn
- $15.80bn
Brief: CSL Seqirus Expands U.S. Availability Of Influenza Vaccine
Brief: CSL Ltd And AWS Collaborate To Advance Biopharmaceutical Research And Development
Australia's CSL taps Amazon's cloud unit to boost research pipeline
Australia's CSL slips on trading ex-dividend, among benchmark's top percentage losers
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Trump administration announces drug pricing deals with CSL, Astellas and others (updated)
Brief: CSL Enters Agreements With U.S. Government To Lower Drug Prices
Trump administration to announce drug pricing deals
Australia shares end flat as BHP, CSL offset banks' decline
Australia's CSL eyes best day in 25 years on strong FY outlook
Brief: Csl FY Adjusted Net Income USD 3,100 Million
Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast (updated)
Australia's CSL reports 2% fall in annual profit
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
US FDA approves first mRNA flu shot from Moderna
Australia's CSL rises as company launches trials for patented manufacturing process
Australia's CSL rises on launching trials for patented manufacturing process